Review



brm 014  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress brm 014
    (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH <t>inhibitor),</t> <t>BRM-014</t> (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.
    Brm 014, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 52 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brm+014/BRM%2FBRG1+ATP+Inhibitor-1/bio_rxiv__64898__2026__03__17__711757-159-21-24
    Average 95 stars, based on 52 article reviews
    brm 014 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "Kinetic proofreading as a mechanism for transcriptional specificity in living human cells"

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells

    Journal: bioRxiv

    doi: 10.64898/2026.03.17.711757

    (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH inhibitor), BRM-014 (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.
    Figure Legend Snippet: (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH inhibitor), BRM-014 (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.

    Techniques Used: Transfection, Knockdown, Confocal Microscopy, Quantitative RT-PCR

    Related Articles

    Transfection:

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells
    Article Snippet: For the RNA-seq experiment , hormone-depleted cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated.cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated. ... For inhibitor perturbations , hormone-depleted cells were pre-treated for 30 min with triptolide (TPL; 50 nM or 100 nM) (Sigma-Aldrich, T3652), BRM-014 (10 μM) (MedChemExpress, HY-119374), or MLN-4924 (500 nM or 1 μM) (Cell Signaling, #85923), followed by 2 h treatment with Dex (100 nM) or vehicle in the continued presence of inhibitor, as indicated.. All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).

    Knockdown:

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells
    Article Snippet: For the RNA-seq experiment , hormone-depleted cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated.cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated. ... For inhibitor perturbations , hormone-depleted cells were pre-treated for 30 min with triptolide (TPL; 50 nM or 100 nM) (Sigma-Aldrich, T3652), BRM-014 (10 μM) (MedChemExpress, HY-119374), or MLN-4924 (500 nM or 1 μM) (Cell Signaling, #85923), followed by 2 h treatment with Dex (100 nM) or vehicle in the continued presence of inhibitor, as indicated.. All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).

    Confocal Microscopy:

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells
    Article Snippet: For the RNA-seq experiment , hormone-depleted cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated.cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated. ... For inhibitor perturbations , hormone-depleted cells were pre-treated for 30 min with triptolide (TPL; 50 nM or 100 nM) (Sigma-Aldrich, T3652), BRM-014 (10 μM) (MedChemExpress, HY-119374), or MLN-4924 (500 nM or 1 μM) (Cell Signaling, #85923), followed by 2 h treatment with Dex (100 nM) or vehicle in the continued presence of inhibitor, as indicated.. All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).

    Quantitative RT-PCR:

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells
    Article Snippet: For the RNA-seq experiment , hormone-depleted cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated.cells were treated with 100 nM dexamethasone (Dex; Sigma-Aldrich, D4902-25MG), 100 nM LG268 (Tocris, Cat. No. 5920), 100 nM AM580 (Tocris, Cat. No. 0760), or 1 μM rosiglitazone (RGZ; Cayman Chemical, Cat. No. 71740) for 2 h or 4 h, as indicated. ... For inhibitor perturbations , hormone-depleted cells were pre-treated for 30 min with triptolide (TPL; 50 nM or 100 nM) (Sigma-Aldrich, T3652), BRM-014 (10 μM) (MedChemExpress, HY-119374), or MLN-4924 (500 nM or 1 μM) (Cell Signaling, #85923), followed by 2 h treatment with Dex (100 nM) or vehicle in the continued presence of inhibitor, as indicated.. All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).All compounds were prepared as stock solutions in DMSO, except Dex, which was dissolved in ethanol, and were diluted into culture medium immediately prior to treatment (final ethanol/DMSO concentration ≤0.1% v/v).



    Similar Products

    brm 014  (MedChemExpress)
    95
    MedChemExpress brm 014
    (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH <t>inhibitor),</t> <t>BRM-014</t> (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.
    Brm 014, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brm+014/BRM%2FBRG1+ATP+Inhibitor-1/bio_rxiv__64898__2026__03__17__711757-159-21-24
    Average 95 stars, based on 1 article reviews
    brm 014 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    dual brm and brg1 inhibitor brm-014  (Cayman Chemical)
    90
    Cayman Chemical dual brm and brg1 inhibitor brm-014
    (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH <t>inhibitor),</t> <t>BRM-014</t> (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.
    Dual Brm And Brg1 Inhibitor Brm 014, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/brm+014/dual+brm+and+brg1+inhibitor+brm+014/pm39616442-219-12-17
    Average 90 stars, based on 1 article reviews
    dual brm and brg1 inhibitor brm-014 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH inhibitor), BRM-014 (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.

    Journal: bioRxiv

    Article Title: Kinetic proofreading as a mechanism for transcriptional specificity in living human cells

    doi: 10.64898/2026.03.17.711757

    Figure Lengend Snippet: (A) Screen readout using smRNA-FISH with ERRFI1 -intronic and MYH9 -3’UTR probes to detect nascent transcription sites in fixed cells. (B) Screening workflow: sgRNAs targeting ∼1,100 genes are transfected in arrayed 384-well plates, followed by 72-hr knockdown, hormone depletion, dexamethasone treatment, and fixation for smFISH. Plates are imaged by spinning confocal microscopy (60X, 9 fields of view/well), and nuclear spots are quantified per cell via automated DAPI segmentation and spot detection. (C) 2D scatter plot of averaged Z-scores (2 replicates) for ERRFI1 (x-axis) and MYH9 (y-axis) nuclear spots, zeroed to the mean of negative controls (sgNEG, sgOR10A5). Hits classified into four categories: “common up” (n=8), “common down” (n=111), “MYH9-specific” (n=16), and “ERRFI1-specific” (n=72). (D) Representative smFISH images for each hit category alongside negative (sgNEG) and positive (sgNR3C1) controls. (E) STRING interaction network of “ERRFI1-specific” hits (left) and representative smFISH images for selected hits (right) (F) RT-qPCR measurement of nascent transcription (intron 1 primers) after 30-min pretreatment with triptolide (TPL; TFIIH inhibitor), BRM-014 (BRM/BRG1 inhibitor), or Pevonedistat (MLN-4924; NEDD8-activating enzyme inhibitor), followed by 2-hr vehicle (left) or 100nM Dex (right) treatment.

    Article Snippet: For inhibitor perturbations , hormone-depleted cells were pre-treated for 30 min with triptolide (TPL; 50 nM or 100 nM) (Sigma-Aldrich, T3652), BRM-014 (10 μM) (MedChemExpress, HY-119374), or MLN-4924 (500 nM or 1 μM) (Cell Signaling, #85923), followed by 2 h treatment with Dex (100 nM) or vehicle in the continued presence of inhibitor, as indicated.

    Techniques: Transfection, Knockdown, Confocal Microscopy, Quantitative RT-PCR